Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Development strategy for new cancer drugs going global (CHN、USA、AUS)
-
The Booming Radiopharmaceuticals Session
Stay tuned
Opening Remarks
Yumin Zhang: Founder, Anchoray Inc.; Radiopharmaceutical Advisor, Tonacea; Honorary Chairman, Chinese American Society of Nuclear Medicine and Molecular Imaging (CASNMMI)
Hong Liu: Director of Scientific Research Management Department, GPHL; Chairman & General Manager, Baiyunshan Rare Nuclide Health
Innovative Design of Radiopharmaceuticals
Zhen Cheng: Director, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Fellow of American Institute for Medical and Biological Engineering, Society for Radiopharmaceutical Sciences, International Society for Optics and Photonics, Royal Society of Chemistry and International Association of Advanced Materials; Vice Chairman, Radiopharmaceuticals Branch, Chinese Nuclear Society
Animal Model Selection for Preclinical-to-Clinical Translation of Radiopharmaceuticals
Conglin Zuo: Founder & Chairman, Hexin Pharmaceutical; Former Vice Chairman, JOINN Laboratories; Member, Drug Toxicology Committee, Chinese Pharmacological Society; Member, Drug Safety Evaluation Research Committee, Chinese Pharmaceutical Association
Clinical Development Strategies for Radiotherapeutic Drugs in Tumor Treatment
Yan Gong: General Manager, Honghong Pharma;Special Advisor for Healthcare Practice, Bain & Company
Synergistic Innovation of RDC and ADC: The Next-Generation Paradigm for Precision Radiopharmaceutical Therapy
Zhican Qu: Chairman, Na'an Biotech
Roundtable 1: Promising Investment Directions for Radiopharmaceuticals Beyond 2026
Tao Xu (Moderator): Founder & CEO, SmartNuclide; Secretary-General, Tonacea Radiopharmaceutical Club
Li Li: Partner, Stars Capital
Chunguang Liu: Managing Partner, Tailong VC
Feng Yu: Founder & CEO, ELI Radiopharma
Gang Chen: Founder & CEO, Jukang Litai
Xun Zhu: Honorary Director-General, Tonacea New Drug Talent Club
Roundtable 2: The Synergy Between Isotopes and Radiopharmaceuticals
Jianguo Li(Moderator): Party Secretary & Deputy Director, China Institute for Radiation Protection (CIRP)
Hong Liu: Chairman, Baiyunshan Rare Nuclide Health
Jim Cai: Chairman & CEO, New Radiomedicine Technology
Bo Shan: CEO, BoomRay Pharmaceuticals
Xiangsheng Ye: Chief Scientific Officer, AlphaGen Therapeutics
Roundtable 3:What Big Pharma Seeks in Radiopharmaceuticals?
Xiang Li (Moderator): Global Partner of Fosun; Senior Vice President, Fosun Pharma; Co-President & Chief Scientific Officer, Innovative Drug Division; CEO, Fosun New Drugs
Wuzhou Wan: President, Central Research Institute, Yunnan Baiyao Group
Fang Li: Director, BD Search & Evaluation, Novartis China
Duan Wang: Director, Frontier Innovation Collaboration, Bayer Pharmaceuticals China Innovation Hub
Peng Yu: Medical Lead, Radiopharmaceutical R&D, AstraZeneca